<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076864</url>
  </required_header>
  <id_info>
    <org_study_id>4-1951/2021</org_study_id>
    <nct_id>NCT05076864</nct_id>
  </id_info>
  <brief_title>Levosimendans Pharmacokinetics in Intensive Care Patients. An Observational Study.</brief_title>
  <acronym>LEFKIP</acronym>
  <official_title>Levosimendans Pharmacokinetics in Intensive Care Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the pharmacokinetics of levosimendan and its metabolites in intensive care&#xD;
      patients with normal, reduced and dialysis supported renal function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aims: To gain a better understanding of the pharmacokinetics of Levosimendan in critically&#xD;
      ill patients and in particular in those patients with and without renal failure and in those&#xD;
      receiving CRRT. This project may give a better basis to determine whether dose monitoring and&#xD;
      adjustment of Levosimendan is necessary to avoid toxicity or under treatment. In order to&#xD;
      study Levosimendan pharmacokinetics, the Karolinska laboratory has in parallel developed a&#xD;
      method for analysis of the substance and its metabolites.&#xD;
&#xD;
      Research questions:&#xD;
&#xD;
        1. To what extent are Levosimendan and its active metabolites dialysable in patients&#xD;
           receiving continuous renal replacement therapy.&#xD;
&#xD;
        2. How do the concentrations of Levosimendan and its active metabolites differ in&#xD;
           critically ill patients with and without acute renal failure?&#xD;
&#xD;
      Method:&#xD;
&#xD;
      The is a prospective observational study conducted on adult intensive care units at&#xD;
      Karolinska University Hospital.&#xD;
&#xD;
      Study Population: Critical care patients who due to clinical need are prescribed Levosimendan&#xD;
      by treating physician will be included into one of three groups based on degree of AKI (KDIGO&#xD;
      classification) and need for CRRT. This is a non-interventional study.&#xD;
&#xD;
      Number of patients to be included: we intend to include 4-12 patients per group.&#xD;
&#xD;
      Procedure: The decision to prescribe Levosimendan will be made by treating physicians as will&#xD;
      decisions regarding dose, dose adjustment and length of treatment.&#xD;
&#xD;
      Screening for inclusion will occur when a decision to prescribe Levosimendan has been made.&#xD;
&#xD;
      Samples of blood, urine and ultrafiltration fluid from the CRRT circuit are to be analysed to&#xD;
      determine concentration of Levosimendan and its metabolites. Plasma concentrations will be&#xD;
      obtained, before and after the dialysis filter.&#xD;
&#xD;
      Concentration monitoring will occur over a period of up to 6 days, with test taken at 0, 6&#xD;
      and 20 hours after infusion start and after cessation of Levosimendan every two hours for the&#xD;
      first 10 hours and there after twice a day for the next 5 days. A maximum of 30 samples (15&#xD;
      in non CRRT patients) of 1-3ml are taken.&#xD;
&#xD;
      Patient groups:&#xD;
&#xD;
      Group 1: Levosimendan + no AKI or KDIGO AKI stage 1. Group 2: Levosimendan + KDIGO AKI stage&#xD;
      2-3, not CRRT Group 3: Levosimendan + KDIGO AKI stage 1-3 with CRRT.&#xD;
&#xD;
      Analysis:&#xD;
&#xD;
      Analysis of the plasma concentration of Levosimendan and its metabolites (OR-1896, OR-1855)&#xD;
      is performed at the clinical pharmacology department, Karolinska University Hospital.&#xD;
      Reference substances have been provided by Orion Pharma.&#xD;
&#xD;
      Definitions:&#xD;
&#xD;
      Acute Kidney Failure (AKI) is defined according to the KDIGO definition: Creatinine entry&#xD;
      from the baseline (percentage increase) and volume of urine production or CRRT treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of levosimendan and OR 1896 1855 in plasma</measure>
    <time_frame>1-5 days</time_frame>
    <description>Plasma concentrations of levosimendan and its active metabolites afte Levosimendan infusion.</description>
  </primary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Metabolites</condition>
  <condition>Intensive Care</condition>
  <condition>Renal Failure</condition>
  <condition>Acute Kidney Injury</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (plasma), Urine, Ultrafiltration fluid.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Intensive Care Unit patients in whom the treating physician has decided due to clinical&#xD;
        indication to administer levosimendan. Dose and length of treatment decided by treating&#xD;
        physician.&#xD;
&#xD;
        With Group 1: No renal failure or Acute Kidney Injury(AKI)* stage 1. Group 2: AKI stage&#xD;
        2-3, not receiving renal replacement therapy. Group 3: Receiving continuous renal&#xD;
        replacement therapy (CRRT)&#xD;
&#xD;
        *AKI classification system Kidney Disease Improving Global outcomes (KDIGO)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Â° Adult Intensive care patients in whom treating physicians have judged to be in need of&#xD;
        Levosimendan treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient &lt;18 years of age&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients receiving Intermittent hemodialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Claire Rimes-Stigare, MD, PhD</last_name>
    <phone>004651770000</phone>
    <email>claire.rimes-stigare@regionstockholm.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susanne Rysz, MD, PhD</last_name>
    <phone>004651770000</phone>
    <email>susanne.rysz@regionstockholm.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne, MD</last_name>
      <phone>004651770000</phone>
      <email>sussanne.rysz@regionstockholm.se</email>
    </contact>
    <contact_backup>
      <last_name>Claire Rimes-Stigare, MD, PhD</last_name>
      <phone>004651770000</phone>
      <email>claire.rimes-stigare@regionstockholm.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Claire Rimes-Stigare</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

